1. Home
  2. AEMD vs AZTR Comparison

AEMD vs AZTR Comparison

Compare AEMD & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEMD

Aethlon Medical Inc.

HOLD

Current Price

$1.96

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.20

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEMD
AZTR
Founded
1984
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1M
2.2M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
AEMD
AZTR
Price
$1.96
$0.20
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$287.50
$4.00
AVG Volume (30 Days)
58.4K
1.8M
Earning Date
02-12-2026
02-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.86
$0.19
52 Week High
$53.60
$2.97

Technical Indicators

Market Signals
Indicator
AEMD
AZTR
Relative Strength Index (RSI) 31.02 27.99
Support Level $2.08 $0.19
Resistance Level $2.32 $0.22
Average True Range (ATR) 0.19 0.02
MACD -0.05 -0.00
Stochastic Oscillator 0.00 2.99

Price Performance

Historical Comparison
AEMD
AZTR

About AEMD Aethlon Medical Inc.

Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: